• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

激肽释放酶基因递送可改善心肌梗死后的心脏储备并减轻重塑。

Kallikrein gene delivery improves cardiac reserve and attenuates remodeling after myocardial infarction.

作者信息

Agata Jun, Chao Lee, Chao Julie

机构信息

Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston 29425, USA.

出版信息

Hypertension. 2002 Nov;40(5):653-9. doi: 10.1161/01.hyp.0000036035.41122.99.

DOI:10.1161/01.hyp.0000036035.41122.99
PMID:12411458
Abstract

In this study, we used the somatic gene delivery approach to explore the role of the kallikrein-kinin system (KKS) in cardiac remodeling and apoptosis after myocardial infarction (MI). Rats were subjected to coronary artery ligation to induce MI, and adenovirus carrying the human tissue kallikrein or luciferase gene was injected into the tail vein at 1 week after surgery. Cardiac output gradually decreased from 2 to 6 weeks after MI, whereas delivery of the kallikrein gene prevented this decrease. Cardiac responses to dobutamine-induced stress were improved in rats receiving kallikrein gene as compared with rats receiving control virus at 6 weeks after MI. Kallikrein significantly improved cardiac remodeling by decreasing collagen density, cardiomyocyte size, and left ventricular internal perimeter and increasing capillary density in the heart at 6 weeks after MI. Kallikrein gene transfer attenuated myocardial apoptosis, which was positively correlated with remodeling parameters in the heart at 2 weeks after MI. Endothelial dysfunction, characterized by increased vascular resistance, decreased left ventricular blood flow, and decreased cardiac nitric oxide levels, existed in remodeled hearts at 2 weeks after MI, whereas kallikrein gene transfer improved these parameters. Kallikrein gene delivery improved cell survival parameters as shown by increased phospho-Akt and reduced caspase-3 activation at 2 weeks after MI. This study indicates that the kallikrein-kinin system plays an important role in preventing the progression of heart failure by attenuating cardiac hypertrophy and fibrosis, improving endothelial function, and inhibiting myocardial apoptosis through the Akt-mediated signaling pathway.

摘要

在本研究中,我们采用体细胞基因递送方法来探究激肽释放酶-激肽系统(KKS)在心肌梗死(MI)后心脏重塑和细胞凋亡中的作用。对大鼠进行冠状动脉结扎以诱导MI,并在术后1周将携带人组织激肽释放酶或荧光素酶基因的腺病毒注入尾静脉。MI后2至6周心输出量逐渐下降,而激肽释放酶基因的递送可防止这种下降。与MI后6周接受对照病毒的大鼠相比,接受激肽释放酶基因的大鼠对多巴酚丁胺诱导的应激的心脏反应得到改善。MI后6周,激肽释放酶通过降低胶原密度、心肌细胞大小和左心室内周长并增加心脏毛细血管密度,显著改善了心脏重塑。激肽释放酶基因转移减轻了心肌细胞凋亡,这与MI后2周心脏中的重塑参数呈正相关。MI后2周,重塑心脏中存在内皮功能障碍,其特征为血管阻力增加、左心室血流量减少和心脏一氧化氮水平降低,而激肽释放酶基因转移改善了这些参数。MI后2周,激肽释放酶基因递送改善了细胞存活参数,表现为磷酸化Akt增加和半胱天冬酶-3激活减少。本研究表明,激肽释放酶-激肽系统通过减轻心脏肥大和纤维化、改善内皮功能以及通过Akt介导的信号通路抑制心肌细胞凋亡,在预防心力衰竭进展中发挥重要作用。

相似文献

1
Kallikrein gene delivery improves cardiac reserve and attenuates remodeling after myocardial infarction.激肽释放酶基因递送可改善心肌梗死后的心脏储备并减轻重塑。
Hypertension. 2002 Nov;40(5):653-9. doi: 10.1161/01.hyp.0000036035.41122.99.
2
Tissue kallikrein and kinin infusion rescues failing myocardium after myocardial infarction.组织激肽释放酶和激肽输注可挽救心肌梗死后衰竭的心肌。
J Card Fail. 2007 Sep;13(7):588-96. doi: 10.1016/j.cardfail.2007.04.009.
3
Human endothelial nitric oxide synthase gene delivery protects against cardiac remodeling and reduces oxidative stress after myocardial infarction.人内皮型一氧化氮合酶基因传递可预防心肌梗死后的心脏重塑并减轻氧化应激。
Life Sci. 2005 Apr 8;76(21):2457-71. doi: 10.1016/j.lfs.2004.11.028.
4
Human tissue kallikrein gene delivery attenuates hypertension, renal injury, and cardiac remodeling in chronic renal failure.人组织激肽释放酶基因传递可减轻慢性肾衰竭中的高血压、肾损伤和心脏重塑。
Kidney Int. 2000 Aug;58(2):730-9. doi: 10.1046/j.1523-1755.2000.00219.x.
5
Nitric oxide mediates cardiac protection of tissue kallikrein by reducing inflammation and ventricular remodeling after myocardial ischemia/reperfusion.一氧化氮通过减轻心肌缺血/再灌注后的炎症反应和心室重构来介导组织激肽释放酶的心脏保护作用。
Life Sci. 2008 Jan 16;82(3-4):156-65. doi: 10.1016/j.lfs.2007.10.021. Epub 2007 Nov 9.
6
Kallikrein/kinin protects against myocardial apoptosis after ischemia/reperfusion via Akt-glycogen synthase kinase-3 and Akt-Bad.14-3-3 signaling pathways.激肽释放酶/激肽通过Akt-糖原合酶激酶-3和Akt-Bad.14-3-3信号通路保护缺血/再灌注后的心肌细胞凋亡。
J Biol Chem. 2005 Mar 4;280(9):8022-30. doi: 10.1074/jbc.M407179200. Epub 2004 Dec 20.
7
Qiliqiangxin improves cardiac function and attenuates cardiac remodeling in rats with experimental myocardial infarction.芪苈强心改善实验性心肌梗死大鼠的心功能并减轻心脏重塑。
Int J Clin Exp Pathol. 2015 Jun 1;8(6):6596-606. eCollection 2015.
8
Kallikrein gene delivery attenuates cardiac remodeling and promotes neovascularization in spontaneously hypertensive rats.激肽释放酶基因递送可减轻自发性高血压大鼠的心脏重塑并促进血管新生。
Am J Physiol Heart Circ Physiol. 2003 Oct;285(4):H1479-88. doi: 10.1152/ajpheart.01129.2002. Epub 2003 Jun 19.
9
Midkine gene transfer after myocardial infarction in rats prevents remodelling and ameliorates cardiac dysfunction.大鼠心肌梗死后中期因子基因转移可防止重塑并改善心功能障碍。
Cardiovasc Res. 2010 Apr 1;86(1):113-21. doi: 10.1093/cvr/cvp386. Epub 2009 Dec 7.
10
Tissue kallikrein promotes neovascularization and improves cardiac function by the Akt-glycogen synthase kinase-3beta pathway.组织激肽释放酶通过Akt-糖原合成酶激酶-3β途径促进新生血管形成并改善心脏功能。
Cardiovasc Res. 2008 Dec 1;80(3):354-64. doi: 10.1093/cvr/cvn223. Epub 2008 Aug 9.

引用本文的文献

1
Two promising approaches in the treatment of myocardial infarction: stem cells and gene therapy.心肌梗死治疗中的两种有前景的方法:干细胞和基因疗法。
Front Cardiovasc Med. 2025 Feb 19;12:1540066. doi: 10.3389/fcvm.2025.1540066. eCollection 2025.
2
Kinin-kallikrein system: New perspectives in heart failure.激肽-激肽释放酶系统:心力衰竭的新视角。
Heart Fail Rev. 2024 May;29(3):729-737. doi: 10.1007/s10741-024-10393-y. Epub 2024 Feb 21.
3
hKLK alleviates myocardial fibrosis in mice with viral myocarditis.人组织激肽释放酶减轻病毒性心肌炎小鼠的心肌纤维化。
J Appl Biomed. 2023 Apr;21(1):15-22. doi: 10.32725/jab.2023.005. Epub 2023 Apr 3.
4
Pre-Conditioning Methods and Novel Approaches with Mesenchymal Stem Cells Therapy in Cardiovascular Disease.预处理方法和间充质干细胞治疗心血管疾病的新方法。
Cells. 2022 May 12;11(10):1620. doi: 10.3390/cells11101620.
5
Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers: Anti-arrhythmic Drug for Arrhythmogenic Right Ventricular Cardiomyopathy.血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂:致心律失常性右室心肌病的抗心律失常药物。
Front Cardiovasc Med. 2021 Nov 12;8:769138. doi: 10.3389/fcvm.2021.769138. eCollection 2021.
6
Estrogen receptor-α prevents right ventricular diastolic dysfunction and fibrosis in female rats.雌激素受体-α可预防雌性大鼠右心室舒张功能障碍和纤维化。
Am J Physiol Heart Circ Physiol. 2020 Dec 1;319(6):H1459-H1473. doi: 10.1152/ajpheart.00247.2020. Epub 2020 Oct 16.
7
The Long-Term Outcome Comparison of Different Time-Delayed Kallikrein Treatments in a Mouse Cerebral Ischemic Model.小鼠脑缺血模型中不同时间延迟激肽释放酶治疗的长期结果比较
Stem Cells Int. 2018 Apr 5;2018:1706982. doi: 10.1155/2018/1706982. eCollection 2018.
8
Overexpression of hexokinase 2 reduces mitochondrial calcium overload in coronary endothelial cells of type 2 diabetic mice.2 型糖尿病小鼠冠状动脉内皮细胞中己糖激酶 2 的过表达可减少线粒体钙超载。
Am J Physiol Cell Physiol. 2018 Jun 1;314(6):C732-C740. doi: 10.1152/ajpcell.00350.2017. Epub 2018 Mar 7.
9
Genetically‑modified stem cells in treatment of human diseases: Tissue kallikrein (KLK1)‑based targeted therapy (Review).基因修饰的干细胞在人类疾病治疗中的应用:组织激肽释放酶 (KLK1) 为基础的靶向治疗(综述)。
Int J Mol Med. 2018 Mar;41(3):1177-1186. doi: 10.3892/ijmm.2018.3361. Epub 2018 Jan 3.
10
Human Tissue Kallikrein Activity in Angiographically Documented Chronic Stable Coronary Artery Disease.血管造影证实的慢性稳定型冠状动脉疾病中的人体组织激肽释放酶活性
Arq Bras Cardiol. 2015 Nov;105(5):457-565. doi: 10.5935/abc.20150109. Epub 2015 Sep 4.